Zosano Pharma ™, Inc., formerly named The Macroflux Corporation, is a private specialty pharmaceutical company creating better products utilizing innovative drug delivery technology.

Zosano’s transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability for various peptides, proteins, small molecules and vaccines.

Based on a small patch and applicator, Zosano’s technology combines rapid drug delivery and good bioavailability with a convenient needle-free administration and a stable room temperature product.

The company’s leading program, a PTH transdermal microprojection patch for osteoporsis, is currently in Phase 2. Other programs are being explored and partnership opportunities also exist.

The company secured $90 million in financing to date from New Enterprise Associates (NEA), Nomura Phase 4 Ventures, HBM BioVentures Partners and ProQuest Investments. Founded in October 2006. Zosano was a Johnson and Johnson Internal Ventures spin-out from the ALZA company.